I don't want to get too excited. But we have an opportunity over time to increase market penetration to levels well above 1%. In addition, we have many products in the pipe, some revolutionary in the fight against antibiotic resistance. To sell this company the offer would need to be considerate of the product pipeline potential and also consider growth potential or we should hold on to this baby until the offer sufficient for those considerations to be realised
Ann: Botanix Commercial Day Webinar Presentation, page-74
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |